Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.

Brabander, Tessa; van der Zwan, Wouter A; Teunissen, Jaap J M; Kam, Boen L R; de Herder, Wouter W; Feelders, Richard A; Krenning, Eric P; Kwekkeboom, Dik J

Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate.

Brabander, Tessa; van der Zwan, Wouter A; Teunissen, Jaap J M; Kam, Boen L R; de Herder, Wouter W; Feelders, Richard A; Krenning, Eric P; Kwekkeboom, Dik J.

Afiliação

Brabander T; Department of Radiology & Nuclear MedicineErasmus Medical Center, Rotterdam, The Netherlands t.brabander@erasmusmc.nl.
van der Zwan WA; Department of Radiology & Nuclear MedicineErasmus Medical Center, Rotterdam, The Netherlands.
Teunissen JJM; Department of Radiology & Nuclear MedicineErasmus Medical Center, Rotterdam, The Netherlands.
Kam BLR; Department of Radiology & Nuclear MedicineErasmus Medical Center, Rotterdam, The Netherlands.
de Herder WW; Department of Internal MedicineENETS Center of Excellence, Erasmus Medical Center, Rotterdam, The Netherlands.
Feelders RA; Department of Internal MedicineENETS Center of Excellence, Erasmus Medical Center, Rotterdam, The Netherlands.
Krenning EP; Department of Radiology & Nuclear MedicineErasmus Medical Center, Rotterdam, The Netherlands.
Kwekkeboom DJ; Department of Radiology & Nuclear MedicineErasmus Medical Center, Rotterdam, The Netherlands.

Endocr Relat Cancer ; 24(5): 243-251, 2017 05.

Article em En | MEDLINE | ID: mdl-28320783

Assuntos

Biomarcadores Tumorais; Tumores Neuroendócrinos/diagnóstico; Tumores Neuroendócrinos/radioterapia; Octreotida/análogos & derivados; Compostos Organometálicos/uso terapêutico; Receptores de Peptídeos/uso terapêutico; Adulto; Idoso; Idoso de 80 Anos ou mais; Biomarcadores Tumorais/metabolismo; Biomarcadores Tumorais/normas; Feminino; Humanos; Masculino; Pessoa de Meia-Idade; Monitorização Fisiológica/métodos; Monitorização Fisiológica/normas; Tumores Neuroendócrinos/patologia; Octreotida/química; Octreotida/uso terapêutico; Compostos Organometálicos/química; Valor Preditivo dos Testes; Prognóstico; Receptores de Peptídeos/química; Estudos Retrospectivos; Adulto Jovem

Palavras-chave

177Lu-DOTATATE; peptide receptor radionuclide therapy (PRRT); response evaluation; toxicity

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos Organometálicos / Octreotida / Biomarcadores Tumorais / Receptores de Peptídeos / Tumores Neuroendócrinos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Endocr Relat Cancer Assunto da revista: ENDOCRINOLOGIA / NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google